Full-Time

Director Public Affairs

Confirmed live in the last 24 hours

Telix Pharmaceuticals

Telix Pharmaceuticals

501-1,000 employees

Develops targeted radiation therapies for cancer

Biotechnology
Healthcare

Expert

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Public Policy

You match the following Telix Pharmaceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree; Advanced degree preferred.
  • 10+ years experience in government affairs, legislative affairs, public policy, or a related field, ideally with specialized knowledge in health and life sciences policy
  • 7+ years experience as a government affairs specialist or lobbyist, either in a corporate, non-profit advocacy, or firm setting, with a proven track record of success supporting issues in the health and life sciences industry
  • Strong understanding of the legislative process with extensive experience working with Congressional offices
  • Deep understanding of pharmaceutical industry regulations, including FDA, CMS, and other relevant agencies
  • Excellent verbal and written communication skills including the ability to develop clear, persuasive policy positions and statements
  • Ability to work collaboratively across departments and with diverse stakeholders
  • Flexibility to travel as needed for meetings, conferences, and events
Responsibilities
  • Develop and execute a comprehensive US government affairs strategy aligned with the company's goals and global government affairs strategy.
  • Identify and prioritize key political and policy issues that impact the organization and its stakeholders.
  • Work with a cross-functional team including legal, regulatory, marketing, market access patient advocacy, and communications in identification of the key issues and to develop strategy.
  • Manage the Telix political action committee (PAC) and define clear objectives such as supporting candidates, influencing legislation, or increasing awareness on key issues.
  • Develop a budget for the PAC that outlines projected contributions, expenses, and fundraising targets, including developing an employee contribution process.
  • Track relevant legislation and regulatory developments at all levels of government using both our in-house public policy platform and external sources, including through leveraging relationships with Congressional and Administration staff.
  • Analyze potential impacts of policy changes on the organization.
  • Prepare briefings for executive leadership and employees.
  • Build and maintain relationships with elected officials and their staff, government agencies, regulatory agencies (HHS/FDA, Energy/NRC, Commerce), industry associations, patient advocacy groups and other key stakeholders.
  • Represent the company at legislative hearings, industry events, fundraisers, and public forums.
  • Craft and disseminate position papers, policy briefs, and other materials to communicate the company’s positions.
  • Prepare presentations for internal and external audiences, including senior leadership and board members.
  • Collaborate with trade associations, customers, physician groups, research organizations, patient groups, and others to build coalitions to advocate for shared interests and amplify the Telix voice.
  • Coordinate grassroots initiatives to mobilize support for key issues among customers and employees.
  • Maintain compliance with all federal, state, and local lobbying laws and regulations.
  • Prepare regular reports on government affairs activities and outcomes for senior management.
  • Maintain PAC in accordance with all applicable laws.
Desired Qualifications
  • Experience in radiopharmaceuticals is a plus.
  • Passion for improving the lives of patients and making a meaningful impact in healthcare.
Telix Pharmaceuticals

Telix Pharmaceuticals

View

Telix Pharmaceuticals develops and sells biopharmaceutical products aimed at improving the diagnosis and treatment of cancer and rare diseases. The company focuses on creating therapeutic and diagnostic solutions that use targeted radiation, which helps healthcare providers make better treatment decisions and offers personalized therapy for patients with significant medical needs. Their product pipeline includes treatments for various types of cancers, such as prostate, kidney, glioma, sarcoma, and bone marrow conditioning. Telix operates a global supply chain to manufacture and distribute its products, generating revenue through sales to healthcare institutions. What sets Telix apart from competitors is its commitment to sustainability, patient care, and ethical practices, which are integrated into its operations. The company's goal is to enhance the quality of life for patients while creating sustainable value for all stakeholders.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$14.8M

Headquarters

Melbourne, Australia

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • Illuccix approval in the UK and Europe boosts Telix's PSMA-PET imaging market presence.
  • Acquisition of ImaginAb's platform enhances Telix's radiotherapeutic technology and product development.
  • Partnership with Curium Pharma expands Scintimun's distribution and market penetration.

What critics are saying

  • Increased competition in PSMA-PET imaging may impact Telix's market share.
  • Integration challenges from ImaginAb acquisition could affect operational efficiency.
  • Gallium-68 supply shortages may disrupt Illuccix production and distribution.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates sustainability and patient care into its biopharmaceutical operations.
  • Telix's global supply chain ensures product availability and delivery worldwide.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-3%
The Manila Times
Feb 13th, 2025
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Telix to showcase urology pipeline at upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025).

PR Newswire
Feb 12th, 2025
Illuccix® Approved In The United Kingdom

MELBOURNE, Australia, Feb. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging[2] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[3] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[4].Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, commented, "PSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network distribution model."Raphaël Ortiz, Chief Executive Officer, Telix International added, "PSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years and we are delighted that we can now bring Illuccix to physicians and their patients across the UK. A key advantage of Illuccix is that the radioisotope (gallium-68) can be produced using a generator locally, taking just a few minutes with minimal equipment

PR Newswire
Jan 22nd, 2025
ImaginAb's Biologics Platform Acquired by Telix

ImaginAb, Inc. has agreed to sell its next-generation therapeutic candidates, biologics technology platform, and research facility to Telix Pharmaceuticals. Post-transaction, ImaginAb will focus on its CD8 ImmunoPET, in Phase 2 trials, and its prostate cancer imaging agent. The sale allows Telix to explore new disease areas with radiotherapeutic technology. Jefferies LLC and Stifel, Nicolaus & Company advised on the transaction.

PR Newswire
Jan 16th, 2025
Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM[2] as Reference Member State (RMS). Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS)[3] agree that Illuccix should receive marketing authorization. The DCP regulatory process will now transition into an administrative national phase to implement authorizations to facilitate commercial launch in each country[4]. Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented, "We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix

Precision Medicine Online
Jan 16th, 2025
Telix Pharmaceuticals Acquires Early-Stage Assets From ImaginAb, Shares Late-Stage Pipeline Updates

NEW YORK - Telix Pharmaceuticals on Monday announced plans to acquire several assets from ImaginAb, including antibodies designed to target DLL3 and integrin αvβ6 as well as several other novel targets.

FNArena
Jan 13th, 2025
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Telix presentation to the 43rd Annual J.P. Morgan Healthcare Conference.

Fierce Biotech
Jan 13th, 2025
Telix continues shopping spree with $45M purchase of ImaginAb's preclinical drugs, facility

Telix continues shopping spree with $45M purchase of ImaginAb's preclinical drugs, facility.

PR Newswire
Jan 13th, 2025
Scintimun® Commercialization Partnership With Curium Pharma

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99mTc-besilesomab, also known as TLX66-CDx), a diagnostic radiopharmaceutical used for infection imaging[1]. The agreement also includes a strategic contract manufacturing agreement appointing Curium as the manufacturer of the product for Telix. Scintimun is an internationally approved product[2] and has previously been manufactured and distributed by Curium Pharma through an out-license from Telix via the acquisition of TheraPharm in 2020[3]. Following a strategic review of the asset, Telix has elected to bring sales and marketing in-house, with plans to significantly augment commercial distribution and indication expansion. The Company also intends to further develop Scintimun as a companion patient selection and safety assessment tool for TLX66 (90Y-besilesomab), its therapeutic bone marrow conditioning candidate for hematopoietic stem cell transplantation (HSCT)

InnovationAus
Jan 13th, 2025
Telix Pharmaceuticals in $73m US IP, infrastructure buy-up

Telix announced on Monday announced it was acquiring intellectual property for a pipeline of early-stage drug candidates that can target cancer cells and a facility in California staffed by a "team of discovery, protein engineering and radiopharmaceutical development experts".

The Market Online
Jan 13th, 2025
ASX Market Update: Bourse falls as Bain Capital ups the ante in fight for Insignia Financial | January 13, 2025

Telix Pharmaceuticals (ASX:TLX) has been up 0.5% has acquired antibody engineering company ImaginAb through a $372M asset buy agreement.

Business News Australia
Jan 13th, 2025
Telix Pharmaceuticals secures $73m deal to acquire US antibody engineering biotech ImaginAb

Telix Pharmaceuticals secures $73m deal to acquire US antibody engineering biotech ImaginAb.

PR Newswire
Jan 12th, 2025
Telix To Acquire Next-Generation Therapeutic Assets And Innovative Biologics Technology Platform

MELBOURNE, Australia and INDIANAPOLIS, Jan. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next-generation therapeutic candidates, proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities. This transaction adds a pipeline of early-stage drug candidates against high-value targets including DLL3[1] and integrin αvβ6[2], as well as several other novel targets in discovery stage. These next generation drug candidates fit synergistically with Telix's therapeutics pipeline, enabling expansion to future therapy areas with unmet clinical need. The acquired intellectual property utilizes small engineered antibody formats that enable highly specific cancer targeting, combined with fast tumor uptake and blood clearance

PR Newswire
Dec 30th, 2024
Noble Registry Update: Tlx599-Cdx Psma Spect Imaging Of Prostate Cancer Published In Ejnmmi Reports

MELBOURNE, Australia and BRUSSELS, Dec. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports

PR Newswire
Dec 19th, 2024
Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete

MELBOURNE, Australia and INDIANAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South, Belgium, facilitating the production of radioisotopes and patient doses on-site from 2025[1]. The installation of cyclotrons from GE Healthcare (Nasdaq: GEHC) and IBA (Ion Beam Applications S.A., EURONEXT), along with proprietary solid targets, establishes TMS Brussels South as a major nuclear medicine production facility, which will serve as the Company's primary manufacturing site for the Europe Middle East and Africa (EMEA) region and beyond. One cyclotron will be dedicated to clinical and commercial supply, and the other to research and development (RD), meaning TMS Brussels South will serve as a vital hub for manufacturing scale-up and production of next generation radiopharmaceuticals, including diagnostics and both alpha- and beta therapeutics[2]. Telix was granted an updated radiation licence in 2022 by the Belgian Federal Agency for Nuclear Control (FANC) for a broad range of commercially important medical isotopes[3]. Both cyclotrons have multi-isotope capacity and will have ARTMS' QUANTM Irradiation System™ (QIS™) installed to support high efficiency, large-scale and cost-effective production